Sales of main products boosts Sanofi-Aventis' profit 1.9% to 1.89B euros

10-11-2008 Comments (0)

ActonelAllegraAmarylAmbienAmbien CRAvaproAventis PharmaBristol-Myers SquibbClopidogrelCopaxonedocetaxelEloxatinEnoxaparin Sodium InjectionFexofenadine HclGlatiramer AcetateGlimepirideHumulin 70-30Humulin NHumulin RInsulinInsulin Glargine [rDNA origin] InjectionirbesartanLantusLovenoxOxaliplatin InjectionPlavixRisedronate SodiumSanofi-AventisTaxotereZolpidem Tartrate

Sanofi-Aventis' third-quarter 2008 profit, adjusted for merger-related costs, rose 1.9% year-on-year…

In order to access this content you need to be logged into the site and have an active subscription or trial subscription.  Please login, take a free trial or subscribe in order to continue reading.

A trial subscription will give you access to the latest news on The Pharma Letter for 7 days, in order to evaluate the paid service.   

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days


PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £70 per month or £720 per year


  • No-limits access to our the site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. Its part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top